Neoadjuvant Chemotherapy for Oropharyngeal Cancer
Author Information
Author(s): Domenge C, Hill C, Lefebvre J L, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B
Primary Institution: Institut Gustave Roussy
Hypothesis
Does neoadjuvant chemotherapy improve survival in patients with oropharyngeal cancer?
Conclusion
Neoadjuvant chemotherapy significantly improves overall survival in patients with oropharyngeal cancer compared to those who do not receive chemotherapy.
Supporting Evidence
- Overall survival was significantly better in the neoadjuvant chemotherapy group than in the control group.
- The median survival was 5.1 years for the chemotherapy group compared to 3.3 years for the no chemotherapy group.
- The effect of neoadjuvant chemotherapy on event-free survival was smaller and of borderline significance.
Takeaway
Giving chemotherapy before surgery or radiation helps people with throat cancer live longer.
Methodology
Multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to loco-regional treatment without chemotherapy.
Participant Demographics
Patients with squamous cell carcinoma of the oropharynx.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website